Back

Serum transthyretin as a prognostic biomarker for cardiovascular events: a systematic review and meta-analysis

30 August 2025 (10:00 - 10:45)
Organised by: Logo
Congress Presentation Part of: New perspectives in cardiology (2) - Cardiac amyloidosis (2) Epidemiology, Prognosis, Outcome ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Mrs Polyxeni Alexiou

Heart Clinic Lucerne, Lucerne (Switzerland)

9 More presentations in this session

Presentation thumbnail
Presentation thumbnail
Doctor A. Sakalidis (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Doctor N. Mora Ayestaran (Pamplona, Navarra, ES)
Abstract Slides Video
Presentation thumbnail
Professor J. Smith (Gothenburg, SE)
Abstract Slides Video
Presentation thumbnail
Doctor L. Hauptmann (Vienna, AT)
Abstract Slides Video

Access the full session

Session thumbnail
New perspectives in cardiology (2) - Cardiac amyloidosis (2)

The Event

Event poster

ESC Congress 2025

30 August 2025 10:00 CET
You may be interested in
thumbnail
Congress Presentation
Beyond stability: unveiling the prognostic and therapeutic role of serum transthyretin in amyloid cardiomyopathy
thumbnail
Congress Presentation
Serum transthyretin before and after starting tafamidis as outcome predictors in ATTR cardiomyopathy
thumbnail
Congress Presentation
Transthyretin stabiliser therapy in patients with transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources